Breaking News

CordenPharma Expands Aseptic/Oral Capabilities

March 18, 2016

Enhances service offerings in the sterile and containment fields 

CordenPharma has completed two investments to strengthen its development and manufacturing capabilities for drug product service offerings across its highly potent, oncology and injectables platforms.

The company completed and received approval of its small-scale aseptic filling line in CordenPharma Caponago. This addition to the existing terminal sterilization capabilities of the manufacturing facility will support customer development and commercial programs by providing expert service in aseptic-filling of liquid and lyophilized vials and pre-filled syringes for small molecules and peptides.

CordenPharma has also completed and received approval of expanded development capabilities (CTD2) for mid-scale—up to 20 kg—contained capacity of highly potent and oncology oral dosage forms in its CordenPharma Plankstadt manufacturing facility. This new and expanded capability provides customers a complete offering in the contained manufacturing of oral dosage from grams to 150 Kg.

“These new investments in oral and aseptic development capacities strengthen our ability to serve customers earlier in the pharmaceutical value chain,” said Ernesto Petroselli, president, CordenPharma. “They are a clear indication of our overall commitment in responding to customers’ needs and are perfect complements to our existing API and drug product service offerings within our highly potent, oncology and injectables platforms.

In addition, Mr. Petroselli said there will be further capacity expansion in the second half of 2016 with the completion of a second pharmaceutical oncology suite in CordenPharma Latina to provide extended supply chain manufacturing services spanning development to commercial scale.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks